Global Innovative Platforms (GIPL) Price to Sales (2025 - 2026)
Global Innovative Platforms' (GIPL) quarterly Price to Sales came in at 490.64 in Q2 2026, up 110.47% quarter-over-quarter from 233.12 in Q1 2026.
Analysis
Global Innovative Platforms (GIPL) Price to Sales (2025 - 2026) Analysis & Trends
Global Innovative Platforms has disclosed Price to Sales across 2 years of filings, most recently posting 490.64 for Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.69 Bn | 40.49 Bn | 779.09 Mn |
| 2 | Zoetis | 30.63 Bn | 28.95 Bn | 1.05 Bn |
| 3 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn |
| 4 | Phibro Animal Health | 1.49 Bn | 1.41 Bn | 134.40 Mn |
| 5 | Immucell | 90.19 Mn | 81.33 Mn | 2.44 Mn |
| 6 | Zhengye Biotechnology Holding | 76.23 Mn | 69.14 Mn | - |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 490.64 |
| Mar 31, 2026 | 233.12 |
| Dec 31, 2025 | 168.59 |